Gianmario Ruos - Agilon Health CEO, Executive Director
| AGL Stock | USD 4.83 0.13 2.62% |
CEO
Dr. Gianmario Tondato da Ruos serves as Chief Executive Officer and Executive Director at Autogrill S.p.A. since March 2003. He joined the Group in 2000 when he moved to the United States to oversee the integration of North American subsidiary HMSHost. He began his career in 1987 with the Mondadori Group and several Benetton Group companies where he handled corporate reorganizations and international mobility. He is Lead independent Director of Lottomatica Group SpA and a Director of Aldeasa SA and Alpha Group Plc. He graduated in Business Economics from the Universita Ca Foscari Venezia. since 2003.
| Age | 55 |
| Tenure | 21 years |
| Address | 6210 East US Highway 290, Austin, TX, United States, 78723 |
| Phone | 562 256 3800 |
| Web | https://www.agilonhealth.com |
Agilon Health Management Efficiency
The company has Return on Asset of (0.0844) % which means that on every $100 spent on assets, it lost $0.0844. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2295) %, meaning that it generated no profit with money invested by stockholders. Agilon Health's management efficiency ratios could be used to measure how well Agilon Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.14. The value of Return On Capital Employed is expected to slide to -0.32. Net Tangible Assets is expected to rise to about 1.1 B this year, although the value of Total Assets will most likely fall to about 1.3 B.Similar Executives
| Found 14 records | CEO Age | ||
| Debra Osteen | Acadia Healthcare | 62 | |
| Theodore CPA | Healthcare Services Group | 50 | |
| Patrick Blair | InnovAge Holding Corp | 53 | |
| Dirk Allison | Addus HomeCare | 68 | |
| Stephen Flatt | National HealthCare | 68 | |
| Michael Doyle | Surgery Partners | 43 | |
| Christopher Christensen | The Ensign Group | 55 | |
| Mark Tarr | Encompass Health Corp | 62 | |
| Bassam Damaj | InnovAge Holding Corp | 47 | |
| Richard Ashworth | Amedisys | 49 | |
| Christopher Reading | US Physicalrapy | 60 | |
| Clifford Adlerz | Surgery Partners | 64 | |
| April Anthony | Encompass Health Corp | 53 | |
| Paul Kusserow | Amedisys | 63 | |
Management Performance
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0844 |
agilon health Leadership Team
Elected by the shareholders, the Agilon Health's board of directors comprises two types of representatives: Agilon Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agilon. The board's role is to monitor Agilon Health's management team and ensure that shareholders' interests are well served. Agilon Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agilon Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gianmario Ruos, CEO, Executive Director | ||
| Steve Johnson, CEO of HMSHost | ||
| Paolo Roverato, Non-Executive Director | ||
| Khadim Hussain, Director | ||
| Andrew Vesey, CEO, Managing Director, Director | ||
| Michelle Gourdine, Independent Director | ||
| Timothy Gertsch, Controller VP | ||
| Brett Redman, CFO | ||
| Sharad Mansukani, Independent Director | ||
| Farooq Khan, Director | ||
| Jacqueline Hey, Non-Executive Director | ||
| Affan Sajjad, Company Secretary | ||
| Mat Varghese, Chief Officer | ||
| Alessandro Benetton, Non-Executive Director | ||
| Muhammad Muzammil, Director | ||
| Ben Shaker, Chief Markets Officer | ||
| Joan Danieley, Chief Administrative Officer | ||
| Matthew CFA, Vice Relations | ||
| Ronald Williams, Non-Executive Chairman of the Board | ||
| Ahmed Bilal, Director | ||
| Mian Said, Director | ||
| Douglas Jackson, Executive General Manager - Group Operations | ||
| Priscilla Kasenchak, Chief Officer | ||
| Paola Bottero, Secretary | ||
| Bruce Phillips, Non-Executive Independent Director | ||
| Jeni Coutts, Executive General Manager - Stakeholder Relations | ||
| Clay Richards, Independent Director | ||
| Stefano Orlando, Lead Independent Director | ||
| Theodore Halkias, Chief Business Officer | ||
| Graeme Hunt, Non-Executive Independent Director | ||
| Girish Venkatachaliah, Chief Technology Officer | ||
| Derek Strum, Director | ||
| Masroor Qureshi, Director | ||
| Francesco Chiappetta, Independent Director | ||
| Belinda Hutchinson, Non-Executive Independent Director | ||
| Denise Zamore, Chief Secretary | ||
| Bilal Asghar, Director | ||
| Michael Smith, Independent Director | ||
| Paul Mcwilliam, Company Secretary | ||
| Tommaso Barracco, Independent Director | ||
| John Hobson, Head of Capital Markets, Investor Relations Contact Officer | ||
| Alessandro Preda, Group Chief HR & Organization Development | ||
| William Wulf, Director | ||
| Benjamin Kornitzer, Chief Medical and Quality Officer | ||
| Claire Mulhearn, Chief Officer | ||
| Alberto Vecchi, CFO, Financial Reporting Officer | ||
| Silvio Girolamo, Group Chief Internal Audit & CSR Officer | ||
| Ernesto Albanese, Independent Director | ||
| Lisa Ali, Chief Officer | ||
| Gilberto Benetton, Non-Executive Chairman of the Board | ||
| Giorgina Gallo, Independent Director | ||
| Daniel Cram, Executive General Manager - People & Culture | ||
| Lisa Dombro, Chief Experience and Innovation Officer | ||
| John Fitzgerald, Company Secretary, Head of Legal | ||
| Ravi Sachdev, Vice Chairman of the Board | ||
| Karen Mcloughlin, Director | ||
| Les Hosking, Non-Executive Independent Director | ||
| Talha Ahmed, Director | ||
| Gianni Mion, Non-Executive Director | ||
| Chris Casler, Chief Human Resource Officer | ||
| Syed Kazmi, Director | ||
| Stephen Mikkelsen, Executive General Manager - Energy Market Operations | ||
| Timothy Bensley, Chief Financial Officer | ||
| Ahsan Durrani, Director | ||
| Elisabetta Cugnasca, Investor Relations Manager | ||
| Neriman Ulsever, Independent Director | ||
| Nauman Ansari, Director | ||
| Veeral Desai, Chief Strategy and Development Officer | ||
| Carolyn Dittmeier, Non-Executive Independent Director | ||
| Jeremy Maycock, Independent Non-Executive Chairman of the Board | ||
| Richard Schnall, Director | ||
| Elizabeth Reese, CFO and Executive VP | ||
| John Stanhope, Non-Executive Independent Director | ||
| Steven Sell, President, Chief Executive Officer, Director | ||
| Alistair Preston, Executive General Manager - Organisational Transformation, Interim Executive General Manager - New Energy | ||
| Massimo Ruffano, Non-Executive Independent Director |
Agilon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agilon Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.0844 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 1.59 B | ||||
| Shares Outstanding | 411.06 M | ||||
| Shares Owned By Insiders | 1.54 % | ||||
| Shares Owned By Institutions | 98.46 % | ||||
| Number Of Shares Shorted | 46.02 M | ||||
| Price To Earning | 23.14 X |
Pair Trading with Agilon Health
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agilon Health position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agilon Health will appreciate offsetting losses from the drop in the long position's value.Moving together with Agilon Stock
| 0.67 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
Moving against Agilon Stock
| 0.68 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.6 | OMI | Owens Minor Earnings Call Today | PairCorr |
| 0.59 | GCTK | GlucoTrack | PairCorr |
| 0.55 | VKTX | Viking Therapeutics | PairCorr |
| 0.49 | DXR | Daxor | PairCorr |
The ability to find closely correlated positions to Agilon Health could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agilon Health when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agilon Health - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling agilon health to buy it.
The correlation of Agilon Health is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agilon Health moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if agilon health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agilon Health can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in agilon health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Agilon Stock please use our How to buy in Agilon Stock guide.Note that the agilon health information on this page should be used as a complementary analysis to other Agilon Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Agilon Stock analysis
When running Agilon Health's price analysis, check to measure Agilon Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agilon Health is operating at the current time. Most of Agilon Health's value examination focuses on studying past and present price action to predict the probability of Agilon Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agilon Health's price. Additionally, you may evaluate how the addition of Agilon Health to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Agilon Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilon Health. If investors know Agilon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agilon Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.951 | Earnings Share (0.48) | Revenue Per Share 10.556 | Quarterly Revenue Growth 0.531 | Return On Assets (0.08) |
The market value of agilon health is measured differently than its book value, which is the value of Agilon that is recorded on the company's balance sheet. Investors also form their own opinion of Agilon Health's value that differs from its market value or its book value, called intrinsic value, which is Agilon Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilon Health's market value can be influenced by many factors that don't directly affect Agilon Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agilon Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agilon Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agilon Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.